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ACTIVITY IN AGE-RELATED MACULAR
DEGENERATION USING OCT
ANGIOGRAPHY
MAYSS AL-SHEIKH, MD,*† NICHOLAS A. IAFE, MD,† NOPASAK PHASUKKIJWATANA, MD, PHD,†‡
SRINIVAS R. SADDA, MD,* DAVID SARRAF, MD‡§
Purpose: To study the qualitative and quantitative features of choroidal neovascular (NV)
membranes in age-related macular degeneration using optical coherence tomography
angiography in patients with active and quiescent NV lesions before and after treatment
with anti–vascular endothelial growth factor.
Methods: Macular optical coherence tomography angiography images were ob-
tained using RTVue XR Avanti with AngioVue. Morphologic features and quantitative
measurements of the NV lesion were analyzed using en face projection images. The NV
lesion was subdivided into inner segment and outer fringe for further fractal dimension
analysis.
Results: In a series of 31 eyes, 11 eyes with active NV lesions at baseline and after
consecutive follow-up after treatment with anti–vascular endothelial growth factor therapy
and 20 eyes with quiescent NV lesions were included in this study. Morphologically, all the
quiescent NV lesions versus 63.6% of the active NV lesions demonstrated a prominent
central vessel and active leasions demonstrated a greater rate of small vessels branching
(82%) and peripheral arcades (82%) than quiescent lesions (30% and 40% respectively)
and this was statistically signiﬁcant. The lesion area and vessel density was not statistically
signiﬁcantly different after treatment or versus quiescent lesions although the latter lesions
were reduced in area. Lesion pattern complexity measured by the fractal dimension was
statistically signiﬁcantly lower in the inner part of the lesion after treatment and statistically
signiﬁcantly lower in the total lesion of the quiescent NV compared with the active NV.
Conclusion: Optical coherence tomography angiography is a new, noninvasive imaging
modality that can be used to perform qualitative and quantitative analyses of NV lesions. In
the future, OCT angiography may provide biomarkers of activity and guide the evaluation
and treatment and monitoring of neovascularization in age-related macular degeneration.
RETINA 0:1–11, 2017
Optical coherence tomography angiography (OCTA)is a novel noninvasive technology that provides
depth-resolved visualization of the retinal and choroi-
dal vasculature without the need for dye injection.1–3
The technology relies on motion contrast to separate
moving from stationary structures and to identify
blood ﬂow. This advanced imaging modality is as
sensitive as dye-based angiography in detecting neo-
vascularization in age-related macular degeneration
(AMD) and provides more information about the
extent and morphology of the neovascular (NV)
lesion.4 Several studies have characterized the detailed
microvascular morphology of the three subtypes of
NV lesions in AMD and have provided unprecedented
structural detail of these abnormal vascular com-
plexes.5–7 Various anatomical descriptors, including
“seafan,” “medusa,” “tangled,” and “dead-tree” mor-
phologies, have been used to characterize Type 1 neo-
vascularization using OCTA analysis, whereas Type 3
lesions have been characterized as small vascular
tufts.7–12
Despite these major technological advances that
have provided incredible descriptive detail of the
various forms of neovascularization in AMD, OCTA
studies have failed to produce guidelines for treatment.
Biomarkers of NV activity using OCTA analysis are
1
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still lacking, and clinical practice continues to rely on
structural OCT biomarkers of activity, including intra-
retinal and subretinal ﬂuid.
Recent studies have used OCTA analysis to eval-
uate the morphologic characteristics of each subtype
of neovascularization in AMD before and after
treatment with anti–vascular endothelial growth fac-
tor (VEGF).5,7,9,13,14 Other studies have found the
sensitivity of OCTA in detecting NV lesions to range
from 50% to 100%.15–18 Liang et al18 described
a correlation of clinical activity versus the detection
of neovascularization on OCTA but not versus the
morphologic appearance. Many groups have observed
the morphologic changes that occur after treatment at
various intervals19–21; however, quantitative compar-
isons between different stages are still limited.
In this study, we performed qualitative and quanti-
tative OCTA analyses of the structural features at
baseline, after anti-VEGF treatment, and in eyes with
clinically quiescent NV lesions.
Methods
This study was approved by the Institutional Review
Board of the University of California, Los Angeles and
conducted in accordance with the ethical standards
stated in the Declaration of Helsinki. The study was
conducted in accordance with the Health Insurance
Portability and Accountability Act regulations. Written
informed consent was obtained from all examined
patients before OCTA imaging.
Study Population
Patients with Type 1 neovascularization secondary
to AMD were enrolled in this study. A comprehensive
chart review was performed to conﬁrm the diagnosis
and subtype of NV (Type 1, 2, or 3). The status of the
disease was determined by a retina specialist (M.A., D.
S.) on the basis of complete ophthalmologic exami-
nation and multimodal imaging, including ﬂuorescein
angiography (Heidelberg Engineering, Germany and
Optos 200Tx; Optos, Scotland, United Kingdom) and
structural OCT (Heidelberg Spectralis HRA + OCT;
Heidelberg Engineering, Heidelberg, Germany).
All patients included in the study were at least 50
years of age, with AMD and Type 1 neovasculariza-
tion associated with pigment epithelial detachment, as
established using ﬂuorescein angiography and spectral
domain OCT at baseline diagnosis. Only those eyes
with clear identiﬁcation of the morphology and extent
of the Type 1 neovascularization on OCTA (as
determined by segmentation at the level of the
choriocapillaris) were enrolled in this study. In
addition, only lesions in which the entire extent of
the lesions could be captured and measured were
included in this study. The presence of any anatomical
changes causing poor visualization of the NV mem-
brane was an exclusion criterion. Intraretinal ﬂuid and
subretinal blood were not exclusion criteria as these
abnormalities did not obstruct identiﬁcation of the
Type 1 NV lesion using OCTA. The cohort of eyes
with AMD and Type 1 neovascularization was then
divided into two groups: eyes with an active neo-
vascularization lesion versus eyes with a quiescent
lesion at the time of baseline examination. Clinical
activity was deﬁned similar to the retreatment criteria
in the pro re nata arm of the HARBOR studies and
included any evidence of disease activity on spectral
domain OCT including presence of intraretinal ﬂuid (i.
e., intraretinal cysts, intraretinal edema, cystoid mac-
ular edema, retinal edema, retinal exudates, and intra-
retinal hemorrhage), the presence of subretinal ﬂuid (i.
e., serous retinal detachment, hemorrhagic retinal
detachment, subretinal hemorrhage, and subretinal
exudates), or presence of subretinal pigment epithelial
ﬂuid (i.e., hemorrhagic retinal pigment epithelium
[RPE] detachment, sub-RPE hemorrhage).22 A con-
secutive follow-up visit with repeat OCTA after treat-
ment with anti-VEGF therapy and the absence of ﬂuid
and other activity signs on structural OCT were
required for enrollment. For the group of patients with
inactive or quiescent neovascularization, the require-
ments included a history of active Type 1 neovascula-
rization treated with anti-VEGF at least 6 months prior
and no signs of activity, either by clinical examination
(i.e., subretinal hemorrhage) or by structural spectral
domain OCT at the time of OCTA acquisition.
Image Acquisition and Analysis
The OCTA images were obtained using a spectral
domain OCT device (RTVue-XR Avanti; Optovue, Inc,
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Fremont, CA) with split-spectrum amplitude decorrela-
tion angiography algorithm.3 The device operated with
a central wavelength of 840 nm, an acquisition speed of
70,000 A-scans per second, and a bandwidth of 45 nm.
The 3 mm · 3 mm scans were obtained with each cube
consisting of 2 repeated volumes of 304 B-scans.
Motion correction was performed using registration of
the two orthogonally captured imaging volumes.23,24
Automatic segmentation was performed by the viewing
software to generate en face projection images of the
NV lesion after adjusting the level of the segmented
layer on the B-scans to best visualize the NV complex.
Two horizontal segmentation lines contoured to the
RPE proﬁle were used to ensure a clear visualization
of the NV complex located deep to the RPE.25 In the
event of segmentation errors, the thickness between the
two segmentation lines was manually adjusted to
include the whole NV complex. The upper line was
located at the level of RPE to avoid a superimposition
of the layers above. The lower line was moved pro-
gressively deeper toward the choroidal–scleral inter-
face. This allowed visualization and analysis of all
structures included in the choroidal en face slab. After
each acquisition, the scans were reviewed for adequate
image quality, motion artifacts, and extent of the NV
membrane in relation to the ﬁeld of view.
Fig. 1. Optical coherence
tomography angiography char-
acteristics to deﬁne morphologic
features of neovascular lesions.
(Upper images) Example of an
active lesion, left eye of a 71-
year-old man. (Upper left).
Optical coherence tomography
angiography en face projection
image of the neovascular com-
plex with vessels radiating in all
directions from the center of the
lesion. Note the presence of tiny
vessels branching from bigger
vessels (arrows), peripheral ar-
cades at the vessel termini
(arrow heads), and the prom-
inent vessel (*). (Upper right)
Corresponding spectral domain
OCT B-scan. (Middle left)
Follow-up OCTA 6 weeks later.
Note the minimal change in the
morphologic features and vessel
density of the neovascular lesion
after anti-VEGF therapy, although
the ﬁner vascular plexus appears
to be attenuated. (Lower images)
Example of a quiescent lesion, left
eye of an 86-year-old female
patient. Visual acuity was 20/30,
status after 17 ranibizumab and 7
aﬂibercept injections, (last injec-
tion 15 months prior). (Lower left)
Note the prominent vessel (*) and
the dilated radiating vessels (ar-
rows) and the absence of branch-
ing tiny vessels and absence of
peripheral arcades of the vessel
termini. Note that the radiating
vessels are more dilated and
demonstrate a straighter caliber.
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Several anatomical features of the NV lesion were
studied and included morphologic patterns such as
a medusa or seafan pattern, branching with tiny
vessels deﬁned as ﬁne anastomoses with numerous
tiny radiating vessels branching from the center to the
periphery, peripheral arcades deﬁned as small anas-
tomotic and looping vessels in the periphery branch-
ing into vascular arcades between the vessel termini,
and presence of prominent central vessels. These
features were analyzed on the en face images
according to previous studies (Figure 1).25 The NV
lesion was divided into an inner segment (inner 80%
of the lesion) and an outer fringe (outer 20% of the
lesion) to quantitatively analyze the differences and
evaluate the location of greatest activity (Figure 2).
Quantitative OCTA analyses, including NV lesion
area and vessel density, were performed using the
publically available software ImageJ (public domain
software; National Institutes of Health, Bethesda,
MD).26 The vessel density of the lesion was calcu-
lated as a ratio of the area occupied by vessels to the
total area of the lesion. Pixel measurements were
then calculated based on the 304-pixel width of the
images. The measured area in pixels was converted
to millimeters based on the scan dimensions (3 mm ·
3 mm scan).
The fractal dimension (FD), a novel parameter used
to evaluate neovascularization activity, enables
Fig. 2. Quantitative measure-
ments of a neovascular lesion
divided into its inner segment
and outer fringe. (Left) Upper
image demonstrates the total
binarized neovascular lesion.
Middle image demonstrates the
outer fringe of the lesion (outer
20%) determined by measuring
the dimensions of the lesion
using ImageJ software and using
the selection tools to shrink the
border of the lesion by 20%
while maintaining the shape.
Lower image demonstrates the
remaining 80% of the lesion
(inner segment). (Right) Corre-
sponding skeletonized images.
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assessment of the architecture of a vascular network,
particularly the degree of pattern complexity.27,28 The
FD was assessed using Fractalyse (TheḾA, Besanco̧n
Cedex, France) after the NV lesion was cropped, bi-
narized, and skeletonized using ImageJ software. The
FD analysis has been shown to be more sensitive when
performed on skeletonized images versus binarized
images.29
Fractalyse software measures the FD using the box-
counting method.30 The box-counting method consists
of dividing a skeletonized image into square boxes of
equal sizes and counting the number of boxes contain-
ing a vessel segment. The process is repeated several
times with boxes of different sizes. The logarithm of
the box size is plotted against the number of boxes
containing a vessel segment using the following
formula:
FD ¼ logðNsÞ=logðsÞ:
In the equation, (Ns) is the number of boxes of
magniﬁcation needed to enclose the structure, (s) is the
size of the boxes. The FD varies with the distribution
of skeletonized vessels of the image and has a value
between 0 and 2 (Figure 3). The more complex the
pattern, the higher the measured value.
All the measurements were made by two indepen-
dent, masked readers (M.A. and N.A.I.). Disagree-
ments over readings were resolved by open
adjudication between readers.
Fig. 3. Fractal dimension measurement (A) OCTA image of an active neovascular (NV) complex after cropping, binarization, and (B) skeletonization.
C. Fractal analysis of the active NV lesion using the box-counting method of Fractalyse. D–F. Corresponding images (the same case as A) of the lesion
after treatment with anti-VEGF therapy. H–I. Corresponding images of a quiescent NV lesion.
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Statistical Analysis
Shapiro–Wilk test was used to evaluate the normal
distribution. A paired samples t test was used to compare
the patient group before and after treatment. An unpaired
t test was used to compare the values to the second group
with the quiescent neovascularization. Chi-square test
was used to compare the categorical parameters. SPSS
statistical software version 21 (SPSS Inc, IBM Com-
pany, Chicago, IL) was used for statistical analysis. A
P value of ,0.05 was considered signiﬁcant.
Results
Thirty-one eyes from 21 patients were included in
this study. Eleven eyes had active neovascularization
at the baseline visit and were treated with anti-VEGF;
2 consecutive follow-up visits were evaluated in this
study. Twenty eyes had quiescent neovascularization
at the time of examination. The mean age in the group
with active neovascularization was 80.8 years (range:
66–91); 7 were men and 4 were women. The mean
number of intravitreal anti-VEGF injections received
before the baseline visit was 14.4. The mean visual
acuity at baseline was 20/50. The period between base-
line and follow-up was 5.181 ± 1.250 weeks (range:
4–7 weeks). In the group with quiescent neovascula-
rization, the mean age was 88.3 years (range: 76–96);
11 were women and 9 were men. The mean number of
intravitreal anti-VEGF injections received before the
baseline visit was 13.2. The mean visual acuity at the
time of enrollment was 20/60. The mean duration of
time since the last anti-VEGF injection was 10.5
months (range 6–36). There was no statistically signif-
icant difference between the two groups regarding age
(P = 0.365), sex (P = 0.545), vision (P = 0.667), and
number of injections at baseline (P = 0.634). Table 1
summarizes the baseline parameters.
Morphologically, of the patients with quiescent NV,
eight had the previously described seafan pattern, ﬁve had
the medusa pattern, and six were indistinct.7 All the le-
sions had a prominent central vessel. Of those with active
Type 1 lesions, two had the seafan pattern (2/2, 100%
with prominent central vessel), ﬁve had the medusa pat-
tern (4/5, 80% with prominent vessel), and four had
indistinct patterns (1/4, 25% with prominent vessel).
Of the 11 eyes with active NV lesions at baseline, 9
(81.81%) showed branching with numerous tiny
vessels at baseline, and 7 (63.63%) showed similar
morphologic changes in the follow-up visit after
treatment with anti-VEGF (P = 0.635). Of the 20 eyes
with quiescent neovascularization, 6 (30%) showed
branching with tiny vessels (P = 0.009).
Of the 11 eyes with active neovascularization at
baseline, 9 (81.81%) showed peripheral arcades. After
treatmeant with anti-VEGF in all the 9 eyes the
peripheral arcades were still visible (P = 1). Of the
20 eyes with a quiescent NV complex, 8 (40%)
showed peripheral arcades at the vessel termini (P =
0.057). The branching vessels in the quiescent lesions
showed a more dilated and straighter caliber and prom-
inent anastomotic connections between large-diameter
vessels. Figures 4 and 5 represent examples of active
neovascularization lesion before and after treatment
with anti-VEGF, and quiescent neovascularization le-
sions with the above-described morphologies.
The mean area of the lesion at baseline was 4.066 ±
2.838 mm2 in the group with active neovasculariza-
tion, 3.901 ± 3.130 mm2 after treatment with
anti-VEGF, and 3.503 ± 2.135 mm2 in the group with
quiescent NV. The vessel density of the lesion was
0.417 ± 0.044 in the group with active lesions before
treatment, 0.412 ± 0.034 after treatment with anti-
VEGF, and 0.433 ± 0.040 in the group of inactive or
quiescent NV. No statistically signiﬁcant difference
was found in lesion area or vessel density between
baseline and follow-up and quiescent lesions (lesion
area P = 0.43, P = 0.538, P = 0.211; vessel density P =
0.42, P = 0.35, P = 0.52) for all eyes (Table 2).
The mean FD in the total area of the active lesion
measured 1.57. The inner segment of the lesion
measured 1.51, and the outer fringe measured 1.38.
The FD in the total area of the lesion in eyes after
treatment was 1.56, and was 1.47 in the inner segment
of the lesion, and was 1.37 in the outer fringe of the
lesion. Statistical signiﬁcance when comparing the FD
of active versus treated lesions was only noted about
the inner segment of the lesion (t test for paired sample
P = 0.126, P = 0.048, P = 0.256, Table 3).
The mean FD in eyes with quiescent NV was 1.44
in the total area, 1.35 in the inner segment, and 1.27 in
the outer fringe. Comparing eyes with quiescent NV
versus those with active NV, statistical signiﬁcance
was noted for all three respective parameters (P =
0.009, P = 0.010, and P = 0.015, Table 3).
Comparing the mean FD between the inner segment
and outer fringe within a lesion, there was no
statistically signiﬁcant difference in the eyes with
Table 1. Baseline Parameters
Active NV Quiescent NV P
Age 80.8 88.3 0.365
Sex
Male/female 7/4 9/11 0.545
No. of injections 14.40 13.2 0.634
Visual acuity 20/50 20/60 0.667
NV, neovascular complex.
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active NV, after receiving treatment, and those with
quiescent NV (P = 0.066, P = 0.148, and P = 0.65).
Discussion
Optical coherence tomography angiography is
a new imaging technology that provides more detailed
microvascular morphologic information and greater
quantitative capability of neovascular lesions in AMD
versus conventional dye–based angiography.4 In our
study, we characterized and analyzed the NV complex
qualitatively and quantitatively, comparing active NV
lesions before and after treatment versus quiescent NV
lesions secondary to AMD.
The morphologic appearance of Type 1 NV did not
differ between the three groups, although there were
a disproportionate number of seafan lesions in the
quiescent group. This ﬁnding was consistent with
a previous study describing a correlation between the
presence of NV on OCTA and clinical activity but no
correlation between the morphologic appearance of
NV and clinical activity.18
A prominent central vessel was visible in all
quiescent NV lesions in our study but was seen in
only seven eyes (63.63%) with active NV. A prom-
inent vessel was found more frequently in eyes with
quiescent NV and is consistent with the maturity and
chronicity of the lesion.7,12 It has been hypothesized
that these prominent vessels have different anatomical
Fig. 4. Type 1 neovascularization in AMD before and after intravitreal anti-VEGF injections. (Upper images) The right eye of an 85-year-old
female patient with visual acuity of 20/80 and status after 16 aﬂibercept injections. (Upper left) Optical coherence tomography angiography en face
projection image of the neovascular complex with vessels radiating in all directions from the center of the lesion (“medusa pattern”). Note the
radiating tiny vessels and the associated ﬁbrovascular pigment epithelium detachment and cystoid macular edema on the structural B-scan OCT.
(Upper right) Follow-up OCTA en face projection 5 weeks later with visual acuity of 20/70. Note the minimal change in vessel density and
morphologic features of the neovascular lesion after anti-VEGF therapy, although the ﬁner vascular plexus appears to be attenuated and the cystoid
macular edema has resolved on the structural B-scan OCT. (Middle images) The right eye of a 78-year-old male patient with visual acuity of 20/60
and status after 3 aﬂibercept injections. (Middle left) Optical coherence tomography angiography en face projection image of the neovascular
complex with vessels radiating from one side of the lesion (seafan pattern). Note the radiating tiny vessels and the peripheral arcades at vessel
termini on OCTA as well as the associated ﬁbrovascular pigment epithelium detachment and subretinal ﬂuid on the structural B-scan OCT. (Middle
right) Follow-up OCTA 6 weeks later with visual acuity of 20/60. Note the minimal change in vessel density and morphologic features after anti-
VEGF therapy, although the ﬁner vascular plexus appears to be attenuated and the subretinal ﬂuid has resolved on the structural B-scan OCT.
(Lower images) The right eye of an 89-year-old female patient with visual acuity of 20/40 and status after 10 aﬂibercept injections. (Lower left)
Optical coherence tomography angiography en face projection image of the neovascular complex with vessels radiating in all directions from the
center of the lesion (medusa pattern). Note the radiating tiny vessels and the peripheral arcades at vessel termini, and the associated ﬁbrovascular
pigment epithelium detachment and subretinal ﬂuid on the structural B-scan OCT. (Lower right) Follow-up OCTA 6 weeks later with visual acuity
of 20/40. Note the minimal change in vessel density and morphologic features after anti-VEGF therapy, although the ﬁner vascular plexus appears
to be attenuated and subretinal ﬂuid has resolved on the structural B-scan OCT.
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ﬁndings that make them more resistant to anti-VEGF
therapy, including endothelial cells that are overlaid
with protective pericytes, in contrast to the small cal-
iber vessels made up of unprotected endothelial cells,
which make them more responsive to
treatment.7,12,31,32
Branching with tiny vessels was noted in 81.81% of
active lesions and in 63.63% of the same eyes after
Fig. 5. Type 1 neovascularization in AMD in quiescent lesions. (Left) The right eye of an 86-year-old female patient with visual acuity of 20/50 and
status after 17 ranibizumab injections (last injection 36 months prior). A 3 mm · 3 mm OCTA en face projection image of a quiescent neovascular (NV)
complex with vessels radiating from one side of the lesion (seafan pattern). Note the prominent vessel and the dilated radiating vessels, and the absence
of branching tiny vessels and absence of peripheral arcades of the vessel termini. Note that the radiating vessels are more dilated and demonstrate
a straighter caliber; (below) corresponding SD OCT B-scan illustrating the corresponding segmentation. (Middle) Left eye of an 89-year-old female
patient with visual acuity of 20/60 and status after 15 ranibizumab and 1 aﬂibercept injection (last injection 36 months prior). A 3 mm · 3 mm OCTA en
face projection image of a quiescent NV complex with vessels radiating in all directions from the center of the lesion (medusa pattern). Note the
prominent vessel and the dilated radiating vessels and the absence of branching tiny vessels and absence of peripheral arcades at the vessel termini;
(below) corresponding segmentation B-scan. (Right) Left eye of an 80-year-old female patient with visual acuity of 20/60 and status after 9 aﬂibercept
injections (last injection 14 months prior). A 3 mm · 3 mm OCTA en face projection image of a quiescent NV complex with vessels radiating in all
directions from the center of the lesion (medusa pattern). Note the prominent vessel and the thick radiating vessels and the presence of branching tiny
vessels but presence of few peripheral arcades at the vessel termini; (below) corresponding segmentation B-scan.
Table 2. Quantitative Measurement of the Lesion Area in mm2, Vessel Density (Ratio), Vessel Density After Dividing Into
Inner Segment and Outer Fringe in mm2 at Baseline of Active Neovascular Lesions, After Treatment With Anti-VEGF, and
Quiescent Lesions
Active NV
Quiescent NVBefore Treatment After Treatment P
Total lesion in mm2 4.066 ± 2.838 3.901 ± 3.130 3.503 ± 2.135 Before vs. after treatment 0.433
Active vs. quiescent 0.538
After treatment vs. quiescent 0.211
Vessel density, ratio
Total lesion 0.417 ± 0.044 0.412 ± 0.034 0.423 ± 0.040 Before vs. after treatment 0.426
Active vs. quiescent 0.351
After treatment vs. quiescent 0.528
Inner segment 0.427 ± 0.069 0.421 ± 0.054 0.421 ± 0.059 Before vs. after treatment 0.514
Active vs. quiescent 0.884
After treatment vs. quiescent 0.075
Outer fringe 0.414 ± 0.0315 0.408 ± 0.0360 0.439 ± 0.051 Before vs. after treatment 0.545
Active vs. quiescent 0.102
After treatment vs. quiescent 0.077
NV, neovascular complex.
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treatment with anti-VEGF; but these vessels were only
noted in 30% of the quiescent NV lesions. This
indicates that this morphologic ﬁnding may not
differentiate active lesions before and after treatment
but may aid in the identiﬁcation of inactive or
quiescent NV lesions. Similar ﬁndings were obtained
with the analysis of peripheral arcades at the vessel
termini. This potential biomarker may help differenti-
ate an active versus a quiescent lesion but may not be
as effective in guiding treatment and differentiating
active NV lesions before and after treatment. Coscas
et al21 have previously identiﬁed these OCTA features
as biomarkers of NV activity, but only in combination
with other OCTA markers. As a single indicator, these
features (e.g., peripheral arcades at the vessel termini)
may not be sufﬁcient to accurately judge activity.
We also found that the radiating vessels in quiescent
lesions were more dilated and demonstrated a straighter
caliber (Figures 1 and 5). This may be explained by
the closure of the smaller vessels (containing unpro-
tected endothelial cells), leading to increased vascular
resistance of the entire NV complex as the remaining
mature vessels (containing pericyte protected endothe-
lial cells) develop higher intraluminal pressure and
ﬂow and, therefore, greater dilation of the vessel
caliber.7,12
Lesion area and vessel density were compared
between the 3 groups and no signiﬁcant difference
was identiﬁed, although quiescent lesions were on
average 15% smaller in area than active lesions.
Moreover, active lesions demonstrated minimal
change after anti-VEGF therapy. Our ﬁndings are
similar to those described by previous studies that
demonstrated only subtle small vessel pruning after
anti-VEGF therapy with subsequent vascular reprolif-
eration or reperfusion as the NV lesion regains
a morphology similar to its morphology before
treatment.7,12,15,19
We used the novel parameter FD to study the
complexity of the NV lesion. The FD measures the
degree of pattern complexity with the box-counting
method by dividing a skeletonized image into square
boxes of equal sizes, where the number of boxes
containing a vessel segment is counted. The FD has
a value between 0 and 2 with higher values indicating
increased pattern complexity. We found a reduced FD
in the inner segment of the lesion when we compared
eyes before and after treatment with anti-VEGF.
Previous studies have noted that the core feeder and
large-caliber vessels remain unchanged after anti-
VEGF treatment, whereas the small-caliber vessels
radiating from the larger trunks are attenuated and
pruned.7,12,13,19,20 Our ﬁnding of a reduced FD after
treatment suggests that the pattern of the NV lesion
after treatment might be less complex due to the atten-
uation and pruning of small-caliber vessels that may
have a less signiﬁcant effect on the vessel density
compared with the large mature vessels.
Comparing eyes with active and quiescent NV,
there was a statistically signiﬁcant difference in the FD
in the total or entire lesion complex and in the inner
segment and outer fringe, suggesting that the vessels
of a quiescent NV lesion show limited branching.
Previous studies have noted that quiescent lesions may
consist of larger, thicker, and straighter vessels.20 We
studied these changes quantitatively and found
a reduced FD, meaning a less complex pattern of
branching associated with quiescent NV (Figures 1
and 3).
Limitations of this study included the small sample
size and the retrospective nature of the analysis with
a lack of uniform follow-up periods. A limitation of
the current OCTA technology is the accuracy of
segmentation algorithms. Manual segmentation to
more accurately locate the NV lesion was not possible,
although the thickness of the segmentation slab was
adjusted. Identiﬁcation and inclusion of the entire NV
complex can be challenging and is critical for accurate
quantitative analysis. This may be further complicated
by projection artifact that especially limits the accu-
racy of quantitation. Accurate repeatability of the
segmentation parameters with follow-up can be
Table 3. Fractal Dimension Measurements of the Active Neovascular Lesions, After Treatment With Anti-VEGF, and
Quiescent Lesions Measured as a Total Area, Inner Segment, and Outer Fringe
Active NV
Quiescent NVBefore Treatment After Treatment P
Total lesion 1.574 ± 0.140 1.560 ± 0.155 1.446 ± 0.110 Before vs. after treatment 0.126
Active vs. quiescent 0.009
Inner segment 1.516 ± 0.180 1.476 ± 0.171 1.351 ± 0.147 Before vs. after treatment 0.048
Active vs. quiescent 0.010
Outer fringe 1.385 ± 0.127 1.374 ± 1.143 1.272 ± 0.111 Before vs. after treatment 0.256
Active vs. quiescent 0.015
NV, neovascularization.
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challenging because of changes in the anatomy that
take place with treatment. Another limitation of the
current technology was motion artifact that can
especially disrupt quantitative measurements. As
SSADA technology relies on the detection of motion
of blood, any movement of the patient’s head or eyes
during image acquisition resulted in varying degrees of
motion artifact and decreased image quality.
In summary, our study provides a comparative
analysis of active NV before and after treatment, and
versus quiescent Type 1 NV secondary to AMD.
Qualitatively, quiescent NV demonstrated a lower inci-
dence of branching of tiny vessels and peripheral
arcades at vessel termini compared with active lesions,
whereas inactive lesions (after treatment) did not differ
morphologically from active lesions. These parameters
may serve as anatomical biomarkers of activity and may
help to differentiate an active lesion that requires
therapy and/or close follow-up versus a quiescent lesion
that does not need treatment and may be monitored less
frequently. Using quantitative fractal analysis, NV
lesion after treatment showed a reduced pattern com-
plexity in the inner segment of the lesion compared with
active NV, whereas quiescent NV showed reduced
complexity in the total lesion area compared with active
lesions before and after treatment. Quantitative fractal
analysis of the branching pattern of NV may provide
additional biomarkers to assess the activity of NV after
anti-VEGF therapy and to determine the quiescent
nature of lesions that do not require treatment. Future
longitudinal studies with larger numbers of patients and
standardized periods of follow-up are necessary to
evaluate the morphologic and quantitative biomarkers
of activity to better guide the treatment and monitoring
of NV lesions in AMD and to more accurately assess
the angiographic response.
In conclusion, OCTA is a new imaging modality
that allows researchers to perform qualitative and
quantitative analyses of NV lesions using a noninva-
sive technique with rapid acquisition. Analyzing the
microvasculature complex and morphologic changes
with OCTA may allow more precise monitoring of
lesions during follow-up and after treatment with anti-
VEGF, to better assess the efﬁcacy of treatment and to
more accurately evaluate the stage of the NV complex.
Key words: OCT angiography, quantitative analy-
sis, fractal dimension, Type 1 neovascularization,
active neovascularization, quiescent neovasculariza-
tion, anti-VEGF.
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